Nifty
Sensex
:
:
10786.90
35510.10
-34.95 (-0.32%)
-179.50 (-0.50%)

Pharmaceuticals & Drugs

Rating :
55/99

BSE: 500087 | NSE: CIPLA

609.15
-6.60 (-1.07%)
25-Jun-2018 | 2:44PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  615.10
  •  622.55
  •  608.00
  •  615.75
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2517204
  •  15333.55
  •  663.40
  •  507.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 49,438.74
  • 35.05
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 52,927.19
  • 0.33%
  • 3.47

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 37.21%
  • 3.01%
  • 16.75%
  • FII
  • DII
  • Others
  • 0.58%
  • 13.61%
  • 28.84%

Chart

Price | P:E | P:BV | EV:EBITDA

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Var%
Dec 17
Dec 16
Var%
Sep 17
Sep 16
Var%
Jun 17
Jun 16
Var%
Net Sales
3,697.97
3,582.00
3.24%
3,913.82
3,647.21
7.31%
4,082.41
3,751.02
8.83%
3,525.05
3,593.72
-1.91%
Expenses
3,141.10
3,075.76
2.12%
3,095.16
2,969.56
4.23%
3,278.02
3,070.31
6.77%
2,878.59
2,982.75
-3.49%
EBITDA
556.87
506.24
10.00%
818.66
677.65
20.81%
804.39
680.71
18.17%
646.46
610.97
5.81%
EBIDTM
15.06%
14.13%
20.92%
18.58%
19.70%
18.15%
18.34%
17.00%
Other Income
40.01
22.79
75.56%
52.93
153.49
-65.52%
113.33
27.23
316.20%
151.38
25.20
500.71%
Interest
35.20
33.40
5.39%
9.15
59.33
-84.58%
42.02
35.16
19.51%
27.86
31.34
-11.10%
Depreciation
284.82
632.19
-54.95%
522.35
257.74
102.67%
302.22
229.18
31.87%
213.43
160.81
32.72%
PBT
199.34
-136.56
-
340.09
514.07
-33.84%
573.48
443.60
29.28%
556.55
444.02
25.34%
Tax
46.15
-75.70
-
-64.23
128.27
-
137.42
71.90
91.13%
130.77
70.81
84.68%
PAT
153.19
-60.86
-
404.32
385.80
4.80%
436.06
371.70
17.32%
425.78
373.21
14.09%
PATM
4.14%
-1.70%
10.33%
10.58%
10.68%
9.91%
12.08%
10.39%
EPS
2.22
-0.77
-
4.98
4.66
6.87%
5.25
4.41
19.05%
5.08
4.54
11.89%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Net Sales
15,219.25
14,394.29
13,594.89
11,345.44
10,173.39
8,279.33
7,020.71
6,323.84
5,359.52
4,960.60
4,010.38
Net Sales Growth
4.43%
5.88%
19.83%
11.52%
22.88%
17.93%
11.02%
17.99%
8.04%
23.69%
 
Cost Of Goods Sold
5,438.42
5,317.12
5,089.86
4,270.63
3,874.83
2,952.61
2,739.30
2,775.18
2,452.98
2,347.40
2,054.39
Gross Profit
9,780.83
9,077.17
8,505.03
7,074.81
6,298.56
5,326.72
4,281.41
3,548.66
2,906.54
2,613.20
1,955.99
GP Margin
64.27%
63.06%
62.56%
62.36%
61.91%
64.34%
60.98%
56.12%
54.23%
52.68%
48.77%
Total Expenditure
12,392.87
11,918.50
11,115.22
9,183.74
8,040.34
6,081.48
5,361.86
4,954.60
4,286.56
4,215.55
3,377.91
Power & Fuel Cost
-
251.73
245.92
228.28
218.63
233.12
235.35
198.55
92.15
91.71
74.69
% Of Sales
-
1.75%
1.81%
2.01%
2.15%
2.82%
3.35%
3.14%
1.72%
1.85%
1.86%
Employee Cost
-
2,633.82
2,434.01
1,967.72
1,542.96
1,036.02
772.50
565.59
289.59
242.91
186.47
% Of Sales
-
18.30%
17.90%
17.34%
15.17%
12.51%
11.00%
8.94%
5.40%
4.90%
4.65%
Manufacturing Exp.
-
1,704.79
1,596.79
737.11
644.42
541.58
583.18
627.94
708.39
676.85
509.42
% Of Sales
-
11.84%
11.75%
6.50%
6.33%
6.54%
8.31%
9.93%
13.22%
13.64%
12.70%
General & Admin Exp.
-
868.31
845.89
743.46
638.08
496.81
369.85
288.71
231.05
193.89
221.14
% Of Sales
-
6.03%
6.22%
6.55%
6.27%
6.00%
5.27%
4.57%
4.31%
3.91%
5.51%
Selling & Distn. Exp.
-
1,009.21
818.76
738.87
680.32
466.22
467.61
386.67
326.48
339.15
282.21
% Of Sales
-
7.01%
6.02%
6.51%
6.69%
5.63%
6.66%
6.11%
6.09%
6.84%
7.04%
Miscellaneous Exp.
-
133.52
83.99
497.67
441.10
355.12
194.07
111.96
185.92
323.64
282.21
% Of Sales
-
0.93%
0.62%
4.39%
4.34%
4.29%
2.76%
1.77%
3.47%
6.52%
1.24%
EBITDA
2,826.38
2,475.79
2,479.67
2,161.70
2,133.05
2,197.85
1,658.85
1,369.24
1,072.96
745.05
632.47
EBITDA Margin
18.57%
17.20%
18.24%
19.05%
20.97%
26.55%
23.63%
21.65%
20.02%
15.02%
15.77%
Other Income
357.65
228.69
208.21
165.55
265.37
222.14
139.52
91.68
353.50
354.49
339.28
Interest
114.23
159.38
206.63
168.29
145.74
33.91
38.34
25.10
28.30
52.23
17.52
Depreciation
1,322.82
1,322.93
754.22
504.71
372.64
330.48
312.22
273.33
167.07
151.79
116.26
PBT
1,669.46
1,222.17
1,727.03
1,654.25
1,880.04
2,055.60
1,447.81
1,162.49
1,231.09
895.52
837.97
Tax
250.11
179.76
331.59
400.03
463.38
544.31
306.51
195.22
243.50
124.50
136.93
Tax Rate
14.98%
14.71%
19.20%
24.18%
24.65%
25.98%
21.17%
16.79%
18.36%
13.90%
16.34%
PAT
1,419.35
1,013.38
1,372.01
1,206.07
1,400.73
1,551.06
1,141.30
967.27
1,082.59
771.02
701.04
PAT before Minority Interest
1,413.31
1,042.41
1,395.44
1,254.22
1,416.66
1,551.06
1,141.30
967.27
1,082.59
771.02
701.04
Minority Interest
-6.04
-29.03
-23.43
-48.15
-15.93
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
9.33%
7.04%
10.09%
10.63%
13.77%
18.73%
16.26%
15.30%
20.20%
15.54%
17.48%
PAT Growth
32.67%
-26.14%
13.76%
-13.90%
-9.69%
35.90%
17.99%
-10.65%
40.41%
9.98%
 
Unadjusted EPS
17.53
12.52
16.93
14.71
17.29
19.24
14.25
12.32
13.70
9.92
9.02

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Shareholder's Funds
12,525.42
11,516.22
10,801.49
10,050.35
9,018.68
7,638.93
6,666.13
5,910.57
4,347.80
3,755.17
Share Capital
160.90
160.68
160.59
160.58
160.58
160.58
160.58
160.58
155.46
155.46
Total Reserves
12,302.48
11,266.12
10,557.74
9,868.12
8,858.10
7,478.35
6,505.55
5,749.99
4,192.34
3,599.71
Non-Current Liabilities
4,513.35
1,407.13
2,417.66
2,028.05
1,024.96
824.27
697.34
184.22
1,104.39
689.60
Secured Loans
0.00
207.00
287.09
317.44
0.00
0.00
15.00
0.41
2.79
14.09
Unsecured Loans
3,645.36
14.88
22.19
0.43
0.55
3.25
2.92
4.66
937.45
526.36
Long Term Provisions
140.52
144.68
1,783.17
1,368.64
713.87
557.78
466.30
0.00
0.00
0.00
Current Liabilities
3,308.07
7,776.05
3,881.13
2,563.58
2,277.63
1,413.19
1,698.54
2,525.63
2,112.37
1,287.80
Trade Payables
1,571.14
1,475.82
1,452.06
979.53
828.36
691.77
720.88
805.41
757.43
533.51
Other Current Liabilities
923.79
1,006.14
654.55
408.67
250.89
489.93
235.28
192.56
255.44
337.48
Short Term Borrowings
467.23
4,969.67
1,392.48
910.47
966.38
10.20
523.06
0.00
0.00
0.00
Short Term Provisions
345.91
324.42
382.04
264.91
232.00
221.29
219.32
1,527.66
1,099.50
416.81
Total Liabilities
20,785.07
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
8,620.42
7,564.56
5,732.57
Net Block
9,472.00
9,368.32
6,829.64
6,496.47
3,609.97
3,215.49
3,094.18
2,011.17
1,992.49
1,661.36
Gross Block
11,305.32
10,167.62
9,561.55
8,676.27
5,317.52
4,626.35
4,240.55
2,897.26
2,693.29
2,201.79
Accumulated Depreciation
1,580.49
799.30
2,731.91
2,179.80
1,707.55
1,410.86
1,146.37
886.09
700.80
540.43
Non Current Assets
11,979.00
12,208.26
9,689.47
9,039.59
5,537.29
4,819.58
4,618.88
2,696.41
2,359.84
1,898.51
Capital Work in Progress
1,682.98
2,060.87
580.90
441.84
377.79
371.17
285.34
684.24
366.32
233.12
Non Current Investment
137.36
176.35
249.76
397.14
415.69
328.59
367.18
1.00
1.03
4.03
Long Term Loans & Adv.
477.35
426.18
1,860.78
1,552.40
978.96
865.38
841.20
0.00
0.00
0.00
Other Non Current Assets
209.31
176.54
168.39
151.74
154.88
38.95
30.98
0.00
0.00
0.00
Current Assets
8,806.07
8,841.23
7,591.29
5,651.97
6,783.98
5,056.81
4,443.13
5,924.01
5,204.72
3,834.06
Current Investments
837.39
582.34
390.02
311.43
2,116.75
940.52
223.59
245.41
79.02
89.45
Inventories
3,485.28
3,808.05
3,780.62
2,895.26
2,387.07
1,850.08
1,906.16
1,512.58
1,398.32
1,120.49
Sundry Debtors
2,497.42
2,356.27
1,997.72
1,638.89
1,668.84
1,553.58
1,490.82
1,566.63
1,852.86
1,406.49
Cash & Bank
624.21
871.40
564.26
175.76
143.01
90.46
95.97
62.06
53.39
79.70
Other Current Assets
1,361.77
437.05
145.60
35.50
468.31
622.17
726.59
2,537.33
1,821.13
1,137.93
Short Term Loans & Adv.
968.64
786.12
713.07
595.13
463.21
459.94
533.77
2,387.57
1,797.68
1,103.44
Net Current Assets
5,498.00
1,065.18
3,710.16
3,088.39
4,506.35
3,643.62
2,744.59
3,398.38
3,092.35
2,546.26
Total Assets
20,785.07
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
8,620.42
7,564.56
5,732.57

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Cash From Operating Activity
2,382.37
1,740.81
1,173.43
1,563.31
1,397.67
1,712.76
1,025.10
1,043.03
374.83
367.00
PBT
1,222.17
1,727.03
1,654.25
1,880.04
2,095.38
1,447.81
1,162.49
1,326.09
896.84
837.97
Adjustment
1,379.75
950.85
630.05
552.80
283.82
396.66
288.84
146.53
252.60
104.48
Changes in Working Capital
230.72
-429.38
-718.61
-561.26
-519.84
199.76
-162.03
-173.82
-708.54
-404.47
Cash after chg. in Working capital
2,832.64
2,248.50
1,565.69
1,871.58
1,859.36
2,044.23
1,289.30
1,298.80
440.90
537.98
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-450.27
-507.69
-392.26
-308.27
-461.69
-331.47
-264.20
-255.77
-64.75
-170.98
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,312.65
-4,522.63
-941.15
-1,249.86
-2,062.89
-965.10
-908.39
-562.75
-580.06
-674.41
Net Fixed Assets
-889.04
1,487.25
-534.38
-437.26
-692.52
-460.09
-601.86
-520.07
-624.70
-562.01
Net Investments
-30.10
164.99
-833.97
-985.31
-1,566.67
-464.50
-305.55
-183.78
13.43
23.05
Others
-393.51
-6,174.87
427.20
172.71
196.30
-40.51
-0.98
141.10
31.21
-135.45
Cash from Financing Activity
-1,323.85
3,104.06
164.78
-265.63
717.77
-753.17
-82.80
-471.61
178.92
254.83
Net Cash Inflow / Outflow
-254.13
322.24
397.06
47.82
52.55
-5.51
33.91
8.67
-26.31
-52.58
Opening Cash & Equivalents
858.15
545.84
175.76
143.01
90.46
95.97
62.06
53.39
79.70
132.28
Closing Cash & Equivalent
610.35
858.15
564.26
175.76
143.01
90.46
95.97
62.06
53.39
79.70

Financial Ratios

Consolidated /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Book Value (Rs.)
154.92
142.23
133.38
124.79
112.21
95.03
82.91
73.50
55.82
48.20
ROA
4.98%
7.28%
7.85%
10.49%
13.97%
12.05%
10.94%
13.38%
11.60%
13.82%
ROE
8.73%
12.61%
12.10%
14.89%
18.64%
15.98%
15.40%
21.14%
19.07%
20.11%
ROCE
8.28%
13.24%
15.33%
19.05%
24.15%
19.96%
18.08%
24.22%
19.82%
22.40%
Fixed Asset Turnover
1.36
1.40
1.26
1.47
1.69
1.61
1.79
1.94
2.05
2.05
Receivable days
60.55
57.62
57.94
58.66
70.11
77.94
87.29
115.32
118.45
108.37
Inventory Days
90.98
100.43
106.36
93.68
92.19
96.16
97.61
98.17
91.54
93.41
Payable days
44.80
48.67
52.17
44.93
48.58
50.51
56.11
69.48
59.02
46.55
Cash Conversion Cycle
106.73
109.38
112.14
107.41
113.72
123.59
128.78
144.01
150.98
155.23
Total Debt/Equity
0.33
0.46
0.16
0.12
0.11
0.00
0.09
0.00
0.22
0.14
Interest Cover
8.67
9.36
10.83
13.90
62.79
38.76
47.31
47.86
18.15
48.83

News Update:


  • Cipla receives approval for Efavirenz Tablets
    20th Jun 2018, 08:50 AM

    Sustiva and its generic equivalents had US sales of approximately $105 million for the 12 month period ending April 2018

    Read More
  • Cipla gets USFDA's approval for Isoproterenol Hydrochloride Injection
    14th Jun 2018, 08:46 AM

    The company's Isoproterenol Hydrochloride Injection USP, 0.2mg/mL, ampoule is APrated generic therapeutic

    Read More
  • Cipla aiming top-line of $1 billion from domestic market in FY19
    11th Jun 2018, 09:52 AM

    The country’s fourth-largest drug maker reported revenues of Rs 15,219 crore in FY18

    Read More
  • Cipla, Unitaid to lower price of the first combination therapy
    8th Jun 2018, 14:32 PM

    Cipla will reduce the ceiling price of the medicine by more than 30% from $3 to $1.99 per person, per month

    Read More
  • Cipla enters into partnership with Eli Lilly
    8th Jun 2018, 14:11 PM

    Lilly’s Basaglar that is manufactured by Lilly will be marketed and distributed in India by Cipla

    Read More
  • Cipla turns black in Q4
    23rd May 2018, 08:47 AM

    Total consolidated income of the company rose 3.69% at Rs 3,737.98 crore for quarter under review

    Read More
  • Cipla gets nod to raise funds
    22nd May 2018, 16:25 PM

    The Board of Directors of the company at their meeting held on May 22, 2018, approved the same.

    Read More
  • Cipla - Quarterly Results
    22nd May 2018, 16:10 PM

    Read More
  • Cipla inks out-licensing deal with Stempeutics Research
    18th May 2018, 15:02 PM

    The company will get exclusive marketing rights for five years in India for critical limb ischemia

    Read More
  • Cipla enters into agreement with MannKind Corporation for Afrezza
    10th May 2018, 08:43 AM

    Cipla will be responsible for obtaining regulatory approvals to distribute Afrezza in India, including approval from the DCGI

    Read More
  • Cipla receives final approval for Phenylephrine Hydrochloride Injection, Exemestane Tablets
    2nd May 2018, 09:15 AM

    The product will be available for shipping in the near future

    Read More
  • USFDA conducts cGMP audit at Cipla’s Indore formulations facility
    17th Apr 2018, 09:55 AM

    The regulator has conducted audit from April 2, 2018 till April 13, 2018

    Read More
  • Cipla’s arm recalls 11 lots of antidepressant bupropion tables from US market
    16th Apr 2018, 08:52 AM

    The ongoing nationwide voluntary recall for both the strengths is on account of failed dissolution specifications; during stability testing

    Read More
  • Cipla launches authorized generic of Aloxi
    26th Mar 2018, 08:41 AM

    Cipla’s Authorized Generic of Aloxi is available for shipping immediately

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.